JP2019501957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501957A5 JP2019501957A5 JP2018543455A JP2018543455A JP2019501957A5 JP 2019501957 A5 JP2019501957 A5 JP 2019501957A5 JP 2018543455 A JP2018543455 A JP 2018543455A JP 2018543455 A JP2018543455 A JP 2018543455A JP 2019501957 A5 JP2019501957 A5 JP 2019501957A5
- Authority
- JP
- Japan
- Prior art keywords
- pdgf
- seq
- amino acids
- breast cancer
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical class 0.000 claims 10
- 239000000328 estrogen antagonist Substances 0.000 claims 9
- 229940000425 combination drug Drugs 0.000 claims 8
- 206010006187 Breast cancer Diseases 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 7
- 108091008606 PDGF receptors Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229960004622 raloxifene Drugs 0.000 claims 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 claims 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- DUDKAZCAISNGQN-UHFFFAOYSA-N Oxyphencyclimine Chemical compound CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 DUDKAZCAISNGQN-UHFFFAOYSA-N 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 229960003437 aminoglutethimide Drugs 0.000 claims 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 1
- 229960002932 anastrozole Drugs 0.000 claims 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 208000010572 basal-like breast carcinoma Diseases 0.000 claims 1
- -1 borozole Chemical compound 0.000 claims 1
- 229960000255 exemestane Drugs 0.000 claims 1
- 229950011548 fadrozole Drugs 0.000 claims 1
- 229960004421 formestane Drugs 0.000 claims 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical group C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 229960003881 letrozole Drugs 0.000 claims 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 1
- 229960002369 oxyphencyclimine Drugs 0.000 claims 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229960005026 toremifene Drugs 0.000 claims 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022011194A JP2022058781A (ja) | 2015-11-10 | 2022-01-27 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1551455 | 2015-11-10 | ||
| SE1551455-7 | 2015-11-10 | ||
| SE1650974-7 | 2016-07-04 | ||
| SE1650974 | 2016-07-04 | ||
| PCT/EP2016/077295 WO2017081171A1 (en) | 2015-11-10 | 2016-11-10 | Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011194A Division JP2022058781A (ja) | 2015-11-10 | 2022-01-27 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501957A JP2019501957A (ja) | 2019-01-24 |
| JP2019501957A5 true JP2019501957A5 (cg-RX-API-DMAC7.html) | 2019-12-19 |
| JP7048505B2 JP7048505B2 (ja) | 2022-04-05 |
Family
ID=57321296
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543455A Active JP7048505B2 (ja) | 2015-11-10 | 2016-11-10 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
| JP2022011194A Pending JP2022058781A (ja) | 2015-11-10 | 2022-01-27 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022011194A Pending JP2022058781A (ja) | 2015-11-10 | 2022-01-27 | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11633382B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3373967B9 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7048505B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108348605B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016352592B2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017081171A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3666276A1 (en) * | 2018-12-14 | 2020-06-17 | dcic Biopharmaceutical Limited | Medication against estrogen-receptor beta (erbeta) positive breast tumor |
| WO2021205405A1 (en) * | 2020-04-10 | 2021-10-14 | Jina Pharmaceuticals, Inc. | Endoxifen for the treatment of bipolar i disorder |
| EP4285938A4 (en) * | 2021-01-29 | 2024-12-25 | Korea Advanced Institute of Science and Technology | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MALIGNANT BREAST CANCER |
| WO2023172891A2 (en) * | 2022-03-07 | 2023-09-14 | Baylor College Of Medicine | Biomarkers for combination therapy for er+ breast cancer |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2464203A (en) | 1943-05-21 | 1949-03-15 | Boots Pure Drug Co Ltd | Manufacture of dienoestrol |
| US2465505A (en) | 1944-12-05 | 1949-03-29 | Hoffmann La Roche | Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4 |
| US2914562A (en) | 1957-08-06 | 1959-11-24 | Wm S Merrell Co | Amine derivatives of triphenylethanol |
| BE637389A (cg-RX-API-DMAC7.html) | 1962-09-13 | |||
| US3822287A (en) | 1969-04-17 | 1974-07-02 | Rexall Drug Chemical | Process for preparation of substituted 3,4-(diphenyl)chromans |
| US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4230862A (en) | 1975-10-28 | 1980-10-28 | Eli Lilly And Company | Antifertility compounds |
| DE2658307C2 (de) | 1976-12-22 | 1979-03-15 | Klinge Pharma Gmbh & Co, 8000 Muenchen | Di-O'-hydroxyphenyD-alkanverbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP0002097B1 (en) | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
| DE3046719C2 (de) | 1980-12-11 | 1983-02-17 | Klinge Pharma GmbH, 8000 München | 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel |
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| GB2126576B (en) | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
| GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| IE58417B1 (en) | 1984-04-27 | 1993-09-22 | Ici Plc | Chemical derivatives |
| GB8517360D0 (en) | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
| US5352795A (en) | 1986-03-07 | 1994-10-04 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
| GB2196003A (en) | 1986-09-11 | 1988-04-20 | Nat Res Dev | Iodo-and bromo-tamoxifen derivatives |
| GB8714013D0 (en) | 1987-06-16 | 1987-07-22 | Ici Plc | (substituted-aralkyl)heterocyclic compounds |
| US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| CA2135160A1 (en) | 1992-05-08 | 1993-11-25 | Masatoshi Inai | Indole derivative |
| TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| GB9326332D0 (en) | 1993-12-23 | 1994-02-23 | Karo Bio | Indole derivatives |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| DE4426625A1 (de) | 1994-07-27 | 1996-03-14 | Schering Ag | 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| US5883118A (en) | 1996-01-11 | 1999-03-16 | Nova Nordisk A/S | Prostatic carcinoma |
| JP2000506505A (ja) | 1996-01-11 | 2000-05-30 | ノボ ノルディスク アクティーゼルスカブ | 閉経期の症状の治療又は予防のための医薬組成物の製造のための３，４―ジフェニルクロマンの使用 |
| JP2001500101A (ja) | 1996-01-11 | 2001-01-09 | ノボ ノルディスク アクティーゼルスカブ | 乳癌の治療及び予防のための医薬組成物の製造のためのセントクロマンのｌ―鏡像異性体の使用 |
| US5726202A (en) | 1996-01-11 | 1998-03-10 | Novo Nordisk A/S | Benign prostatic hypertrophy |
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| US5985910A (en) | 1996-04-19 | 1999-11-16 | American Home Products Corporation | 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents |
| US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| ZA982819B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. |
| ZA982818B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Prevention of breast cancer using selective estrogen receptor modulators. |
| ZA982877B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| US6509356B1 (en) | 1997-08-07 | 2003-01-21 | Eli Lilly And Company | 1-(4-(Substituted alkoxy)benzyl)naphthalene compounds having estrogen inhibitory activity |
| PE20000129A1 (es) | 1997-12-23 | 2000-03-11 | Schering Ag | 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa |
| US6548491B2 (en) | 1997-12-24 | 2003-04-15 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| US6069153A (en) | 1998-05-12 | 2000-05-30 | American Home Products Corporation | Indenoindoles and benzocarbazoles as estrogenic agents |
| ATE315033T1 (de) | 1998-08-07 | 2006-02-15 | Chiron Corp | Subtituierte isoxazole derivate als estrogen rezeptor modulatore |
| TW593256B (en) | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| US6340774B1 (en) | 2000-01-31 | 2002-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Non-steroidal estrogen-receptor antagonists |
| DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| WO2001098322A1 (en) | 2000-06-22 | 2001-12-27 | Northeastern University | Novel steroidal antiestrogens and antiandrogens and uses thereof |
| US6750213B2 (en) | 2000-10-19 | 2004-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| US6599921B2 (en) | 2001-02-22 | 2003-07-29 | Nanodesign, Inc. | Non-steroidal estrogen receptor ligands |
| US6927224B2 (en) | 2001-08-11 | 2005-08-09 | Bristol Myers Squibb Company | Selective estrogen receptor modulators |
| WO2003015761A1 (en) | 2001-08-13 | 2003-02-27 | Merck & Co., Inc. | Selective estrogen receptor modulators |
| JP4554219B2 (ja) | 2002-04-24 | 2010-09-29 | メルク・シャープ・エンド・ドーム・コーポレイション | エストロゲン受容体調節剤 |
| WO2005087812A1 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Multivalent antibody materials and methods for vegf/pdgf family of growth factors |
| AR051597A1 (es) | 2004-11-01 | 2007-01-24 | Merck & Co Inc | Moduladores de los receptores de estrogeno |
| US8147828B2 (en) | 2006-04-17 | 2012-04-03 | Ludwig Institute For Cancer Research | Methods and compositions for modulation of blood-neural barrier |
| CA2663571A1 (en) * | 2006-09-13 | 2008-03-20 | Nuvelo, Inc. | Methods for treating cancer |
| WO2008099060A2 (en) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
| US7732491B2 (en) * | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| JP2013525296A (ja) | 2010-04-16 | 2013-06-20 | ノバルティス アーゲー | 内分泌療法抵抗性乳癌の処置 |
| US9884910B2 (en) * | 2012-04-24 | 2018-02-06 | Thrombogenics Nv | Anti-PDGF-C antibodies |
| WO2014070523A1 (en) | 2012-11-02 | 2014-05-08 | Repros Therapeutics Inc. | Trans-clomiphene for use in cancer therapy |
-
2016
- 2016-11-10 US US15/774,341 patent/US11633382B2/en active Active
- 2016-11-10 JP JP2018543455A patent/JP7048505B2/ja active Active
- 2016-11-10 AU AU2016352592A patent/AU2016352592B2/en active Active
- 2016-11-10 CN CN201680065636.1A patent/CN108348605B/zh active Active
- 2016-11-10 EP EP16795300.9A patent/EP3373967B9/en active Active
- 2016-11-10 WO PCT/EP2016/077295 patent/WO2017081171A1/en not_active Ceased
-
2022
- 2022-01-27 JP JP2022011194A patent/JP2022058781A/ja active Pending
-
2023
- 2023-03-14 US US18/121,075 patent/US20230310385A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502120A5 (cg-RX-API-DMAC7.html) | ||
| Bringhen et al. | New agents in multiple myeloma: an examination of safety profiles | |
| JP2018508516A5 (cg-RX-API-DMAC7.html) | ||
| EP4509527A3 (en) | Post-translationally modified fully human antibody therapeutic agents | |
| RU2017140674A (ru) | Способы лечения рака | |
| JP2014525465A5 (cg-RX-API-DMAC7.html) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| JP2017530983A5 (cg-RX-API-DMAC7.html) | ||
| JP2019501957A5 (cg-RX-API-DMAC7.html) | ||
| BR112018071585A2 (pt) | formulações de um inibidor de lsd1 | |
| JP2016536286A5 (cg-RX-API-DMAC7.html) | ||
| MX2021001143A (es) | Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo. | |
| JP2014511383A5 (cg-RX-API-DMAC7.html) | ||
| JP2019532047A5 (cg-RX-API-DMAC7.html) | ||
| JP2017518302A5 (cg-RX-API-DMAC7.html) | ||
| MX392487B (es) | Métodos y composiciones para dosificación en terapia celular adoptiva. | |
| JP2015500887A5 (cg-RX-API-DMAC7.html) | ||
| NZ749192A (en) | Ar+ breast cancer treatment methods | |
| JP2017113019A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516074A5 (cg-RX-API-DMAC7.html) | ||
| MX2018011054A (es) | Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3. | |
| JP2017514853A5 (cg-RX-API-DMAC7.html) | ||
| JP2017501848A5 (cg-RX-API-DMAC7.html) | ||
| JP2019530706A5 (cg-RX-API-DMAC7.html) | ||
| RU2017116070A (ru) | Способ лечения первичного гормонорезистентного эндометриального рака и рака груди |